(a).
| Distribution of SML symptom severity | ||||||
|---|---|---|---|---|---|---|
| Group | 1, none or slight | 2, mild | 3, moderate | 4, severe | 5, very severe | |
| Before intervention | BrainPower group | 0 (0%) | 3 (6.4%) | 16 (34.0%) | 17 (36.2%) | 11 (23.4%) |
| Placebo group | 5 (9.8%) | 7 (13.7%) | 7 (13.7%) | 25 (49.0%) | 7 (13.7%) | |
| Total | 5 (5.1%) | 10 (10.2%) | 23 (23.5%) | 42 (42.9%) | 18 (18.4%) | |
|
| ||||||
| After intervention | BrainPower group | 2 (4.3%) | 14 (29.8%) | 18 (38.3%) | 11 (23.4%) | 2 (4.3%) |
| Placebo group | 2 (3.9%) | 12 (23.5%) | 27 (52.9%) | 10 (19.6%) | 0 (0%) | |
| Total | 4 (4.1%) | 26 (26.5%) | 45 (45.9%) | 21 (21.4%) | 2 (2.0%) | |